Short Interest in NewAmsterdam Pharma (NASDAQ:NAMSW) Drops By 71.4%

NewAmsterdam Pharma (NASDAQ:NAMSW) saw a large decrease in short interest in the month of November. As of November 30th, there was short interest totalling 1,000 shares, a decrease of 71.4% from the November 15th total of 3,500 shares. Based on an average daily volume of 6,800 shares, the short-interest ratio is presently 0.1 days.

Institutional Trading of NewAmsterdam Pharma

An institutional investor recently bought a new position in NewAmsterdam Pharma stock. TFC Financial Management Inc. bought a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMSW) in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 10,000 shares of the company’s stock, valued at approximately $87,000.

NewAmsterdam Pharma Price Performance

Shares of NewAmsterdam Pharma stock traded down $0.03 during trading on Wednesday, hitting $14.07. 4,037 shares of the company were exchanged, compared to its average volume of 10,144. The firm’s fifty day moving average price is $9.70 and its 200 day moving average price is $8.57. NewAmsterdam Pharma has a 1-year low of $2.38 and a 1-year high of $16.75.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.